search
Back to results

Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography (CIN)

Primary Purpose

Contrast Induced Nephropathy

Status
Unknown status
Phase
Phase 3
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Atorvastatin
Sponsored by
Isfahan University of Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Contrast Induced Nephropathy focused on measuring coronary angiography, chronic stable angina, CIN

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All Sexes

Inclusion Criteria:

  • having chronic stable angina who were referred for coronary angiography
  • non-pregnant female subjects
  • no history of diabetes mellitus
  • no history of renal failure
  • no history of single kidney
  • no history of cardiogenic shock
  • no history of unstable angina
  • no history of myocardial infarction
  • no history of hypersensitivity to statins
  • no history of previous intravascular contrast injection during one month before admission

Exclusion Criteria:

  • glomerular filtration rate (GFR) <60
  • cardiogenic shock

Sites / Locations

  • Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

No Intervention

Experimental

Arm Label

placebo group

long term statin group

preoperation statin group

Arm Description

taking atorvastatin like placebo 12 hours before the procedure

taking atorvastatin for a long time before entering the study (their routine treatment)

taking atorvastatin 12 hours before the procedure

Outcomes

Primary Outcome Measures

Contrast induced nephropathy (CIN) incidence
CIN is determined as an increase in post-procedural serum creatinine of > 0.5 mg/dl or > 25% from baseline in the absence of any other causes

Secondary Outcome Measures

serum creatinine (Cr) level

Full Information

First Posted
April 5, 2014
Last Updated
April 10, 2014
Sponsor
Isfahan University of Medical Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT02113540
Brief Title
Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography
Acronym
CIN
Official Title
Atorvastatin and Prevention of Contrast Induced Nephropathy Following Coronary Angiography
Study Type
Interventional

2. Study Status

Record Verification Date
April 2014
Overall Recruitment Status
Unknown status
Study Start Date
January 2012 (undefined)
Primary Completion Date
May 2014 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Isfahan University of Medical Sciences

4. Oversight

5. Study Description

Brief Summary
As the effect of statin use before the angiography to prevent contrast induced nephropathy (CIN) is not well-known, the aim of the current study is to assess the effect of atorvastatin on prevention of CIN in patients undergoing coronary angiography.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Contrast Induced Nephropathy
Keywords
coronary angiography, chronic stable angina, CIN

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized

8. Arms, Groups, and Interventions

Arm Title
placebo group
Arm Type
Placebo Comparator
Arm Description
taking atorvastatin like placebo 12 hours before the procedure
Arm Title
long term statin group
Arm Type
No Intervention
Arm Description
taking atorvastatin for a long time before entering the study (their routine treatment)
Arm Title
preoperation statin group
Arm Type
Experimental
Arm Description
taking atorvastatin 12 hours before the procedure
Intervention Type
Drug
Intervention Name(s)
Atorvastatin
Primary Outcome Measure Information:
Title
Contrast induced nephropathy (CIN) incidence
Description
CIN is determined as an increase in post-procedural serum creatinine of > 0.5 mg/dl or > 25% from baseline in the absence of any other causes
Time Frame
48 hours after the procedure
Secondary Outcome Measure Information:
Title
serum creatinine (Cr) level
Time Frame
48 hours after the procedure

10. Eligibility

Sex
All
Eligibility Criteria
Inclusion Criteria: having chronic stable angina who were referred for coronary angiography non-pregnant female subjects no history of diabetes mellitus no history of renal failure no history of single kidney no history of cardiogenic shock no history of unstable angina no history of myocardial infarction no history of hypersensitivity to statins no history of previous intravascular contrast injection during one month before admission Exclusion Criteria: glomerular filtration rate (GFR) <60 cardiogenic shock
Facility Information:
City
Isfahan
Country
Iran, Islamic Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
payman bidram, resident, MD
Phone
0989131102802
Email
pbidram2000@yahoo.com

12. IPD Sharing Statement

Learn more about this trial

Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography

We'll reach out to this number within 24 hrs